Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

5'-Guanidinonaltrindole

Introduction

Overview

Overview

5′-Guanidinonaltrindole (GNTI) is an opioid antagonist used in scientific research which is highly selective for the Îș opioid receptor. It is 5x more potent and 500 times more selective than the commonly used Îș-opioid antagonist norbinaltorphimine.[1] It has a slow onset and long duration of action,[2][3] and produces antidepressant effects in animal studies.[4] It also increases allodynia by interfering with the action of the Îș-opioid peptide dynorphin.[5]

References

References

  1. ↑ Jones RM, Portoghese PS. 5′-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist. European Journal of Pharmacology. 2000 May 12;396(1):49-52. PMID 10822054
  2. ↑ Negus SS, Mello NK, Linsenmayer DC, Jones RM, Portoghese PS. Kappa opioid antagonist effects of the novel kappa antagonist 5′-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys. Psychopharmacology (Berlin). 2002 Oct;163(3-4):412-9. PMID 12373442
  3. ↑ Bruchas MR, Yang T, Schreiber S, Defino M, Kwan SC, Li S, Chavkin C. Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. Journal of Biological Chemistry. 2007 Oct 12;282(41):29803-11. PMID 17702750
  4. ↑ Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr, Jones RM, Portoghese PS, Carlezon WA Jr. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. Journal of Pharmacology and Experimental Therapeutics. 2003 Apr;305(1):323-30. PMID 12649385
  5. ↑ Obara I, Mika J, Schafer MK, Przewlocka B. Antagonists of the kappa-opioid receptor enhance allodynia in rats and mice after sciatic nerve ligation. British Journal of Pharmacology. 2003 Oct;140(3):538-46. PMID 12970097

Template:Opioids

Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]